Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 13, 2023 4:55pm
248 Views
Post# 35783165

RE:RE:Where is Andrew de Guttadauro

RE:RE:Where is Andrew de Guttadauro

So, Andrew G. Head of USA operations & business development officer has been gone for a week.
No N.R. On that.
Quite frankly executives come & go all the time @ companies. Sometimes a N.R. Most times not.
So, we ponder?
Good news, bad or insignificant?
first of all 100% speculstion & imho:


I always like to lead with the good news. Assuming a buyout is in the negotiations & very close. He would be loosing his job @ completion, of the deal.
Perhaps, knowing that has moved on. Before the buyout. Could even be part of the " deal"

insignificant?
Could be he is retiring or moving on to a better offer.

Bad options? Endless as far as anyone's imagination can muster.
He could be getting pushed aside for lack of a deal. He may have been given a timeline. 
Could be as part of recent near 10% ownership of recent mutual fund ( $15 million only sold in Canada), they have decided to be Canadian only, again.
That is a complicated thought, with wide & far implications.

Considering Matt exercised his 350,000 options. Is clear evidence the roof is not falling in.
Regardless now that the cat is out of the bag. There will be news to follow.
Could be great, bad or insignificant.

back when Michael Moore left the I.R. Position there was zero discussion, until he was replaced.
To the the best of my understanding M.M. Left To go to a better position.

All of the recent science reports are very positive. Onc/ Pela will live or die on the science.
So we wait.

 

<< Previous
Bullboard Posts
Next >>